logo
Plus   Neg
Share
Email

ViiV Healthcare: GEMINI 1&2 Studies Meets Primary Endpoint - Quick Facts

ViiV Healthcare reported positive headline results from its phase III GEMINI study programme. The studies (GEMINI-1 and GEMINI-2) are designed to evaluate the safety and efficacy of a two-drug regimen of dolutegravir and lamivudine compared to a three-drug regimen of dolutegravir and two nucleoside reverse transcriptase inhibitors, tenofovir disoproxil fumarate/emtricitabine, in treatment naïve HIV-1 infected adults with baseline viral loads less than 500,000 copies per ml. The company said the studies met their primary endpoint for non-inferiority based on plasma HIV-1 RNA <50 copies per millilitre, a standard measure of HIV control, at Week 48.

The company said the safety results for the 2DR of dolutegravir and lamivudine were consistent with the product labelling for the medicines. No patient who experienced virologic failure in either treatment arm developed treatment-emergent resistance.

Full results from the studies will be presented at an upcoming scientific meeting. ViiV will now plan for regulatory submissions for the two-drug regimen of dolutegravir and lamivudine later in the current year.

For comments and feedback contact: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Walmart Inc. is expanding two-day shipping and in-store returns to millions of items sold by third-party sellers on its website, just ahead of the busy holiday shopping season. The company noted that these major improvements to its marketplace will begin to roll out in November. The free two-day shipping will be available on orders over $35. Verizon Communications Inc. (VZ) reported a profit for the third-quarter 2018 that increased 36.0 percent from last year. Total operating revenues rose 2.8 percent from last year. Both adjusted earnings per share and quarterly revenues topped analysts' expectations. It is on track to deliver against a goal to achieve $10 billion in cumulative cash savings by 2021. Shares of Groupe Renault declined around 3 percent in the morning trading in Paris after the French automaker reported weak revenues in its third quarter. Further, the company confirmed its guidance for fiscal 2018, and adjusted growth view for certain markets. Renault continues to expect increase in full-year Group revenues at constant exchange rates and perimeter.
Follow RTT